Retatrutide vs Tirzepatide vs Semaglutide: Receptor Pharmacology in Research

For laboratory research use only. Research-grade retatrutide, tirzepatide and semaglutide supplied by BioRhex are not FDA-approved products and are not intended for human or animal administration. This article compares published receptor pharmacology and makes no claims about effects in humans.

Retatrutide, tirzepatide and semaglutide are three of the most studied incretin-pathway peptides in metabolic research. The key difference between them is how many receptors each one engages: semaglutide is a single GLP-1 receptor agonist, tirzepatide is a dual GIP/GLP-1 receptor agonist, and retatrutide is a triple GIP/GLP-1/glucagon receptor agonist. This comparison covers their structures, receptor profiles and how laboratories use them as tool compounds.

At a glance

Semaglutide: the single-agonist reference compound

Semaglutide is a GLP-1 analogue engineered for a long half-life. Its discovery paper describes two design changes: amino acid substitutions that resist DPP-4 degradation, and a C-18 fatty diacid side chain that binds albumin (Lau et al., 2015). Because it acts on one receptor, semaglutide is widely used as the GLP-1R-selective comparator in multi-agonist studies.

Tirzepatide: dual GIP and GLP-1 receptor agonism

Tirzepatide is a 39-amino-acid peptide built on the GIP sequence and modified to also activate the GLP-1 receptor. Its discovery work characterized it as an “imbalanced” dual agonist, with GIP receptor potency comparable to native GIP and weaker GLP-1 receptor potency than native GLP-1 (Coskun et al., 2018). That profile makes tirzepatide a useful tool for studying how GIP signaling adds to GLP-1 signaling. A head-to-head clinical comparison with semaglutide has also been published (Frías et al., 2021).

Retatrutide: adding the glucagon receptor

Retatrutide extends the multi-agonist approach to a third receptor. Its discovery paper reports agonism at GIP, GLP-1 and glucagon receptors, with GIP receptor potency greater than native GIP and lower relative potency at GLP-1 and glucagon receptors (Coskun et al., 2022). Glucagon receptor activity is the research interest here: it is studied for its role in energy expenditure and hepatic lipid metabolism, which is why retatrutide also appears in liver-fat research (Sanyal et al., 2024). Phase 2 trial literature has been published (Jastreboff et al., 2023).

How laboratories use the three together

• Receptor dissection: comparing a single, dual and triple agonist helps isolate the contribution of each receptor in cell-based cAMP assays or receptor-knockout models.
• Selectivity controls: semaglutide serves as the GLP-1R-only control when testing GIPR or GCGR contributions.
• Hepatic and adipocyte models: retatrutide is used where glucagon receptor signaling is the variable of interest.

For multi-compound studies, the Metabolic Research Stack groups related compounds with matched batch documentation.

What to check when sourcing incretin peptides

These are long, lipidated peptides, so synthesis quality varies more than with short sequences. Confirm a batch COA with HPLC purity (≥99% main peak) and a mass spectrometry result matching the expected molecular weight — about 4,114 Da for semaglutide, 4,814 Da for tirzepatide and 4,731 Da for retatrutide. Our article on how peptide purity impacts research consistency explains why this matters for reproducible data.

All three are available in the BioRhex Metabolic Pathway Research category, US-manufactured and shipped with a batch-specific COA.

References

1. Lau J, Bloch P, Schäffer L, et al. (2015). Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry, 58(18), 7370–7380. https://doi.org/10.1021/acs.jmedchem.5b00726
2. Coskun T, Sloop KW, Loghin C, et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. https://doi.org/10.1016/j.molmet.2018.09.009
3. Coskun T, Urva S, Roell WC, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism, 34(9), 1234–1247.e9. https://doi.org/10.1016/j.cmet.2022.07.013
4. Frías JP, Davies MJ, Rosenstock J, et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
5. Jastreboff AM, Kaplan LM, Frías JP, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
6. Sanyal AJ, Kaplan LM, Frías JP, et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature Medicine, 30(7), 2037–2048. https://doi.org/10.1038/s41591-024-03018-2